Can I Take Green Tea Extract (EGCG) with MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and Why Do People Stack It with Green Tea?

MK-677, also called ibutamoren, is an orally active ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) release and raises insulin-like growth factor 1 (IGF-1). Researchers first characterized it in the mid-1990s, and a Merck-sponsored trial published in 1998 showed that 25 mg daily for 2 years significantly increased GH and IGF-1 in older adults without serious adverse events at that dose [1]. It has never received FDA approval, so it is sold as a "research chemical."

Green tea extract standardized for epigallocatechin gallate (EGCG) is one of the most widely purchased supplements globally. Users pair it with MK-677 for several reasons: EGCG has documented anti-inflammatory and antioxidant properties, it may modestly support fat oxidation, and some users believe it offsets the water-retention or appetite-stimulating effects of ibutamoren.

The pairing sounds harmless on paper. The real question is whether these two compounds interact in ways that matter clinically.

How MK-677 Works

Ibutamoren binds the ghrelin receptor (GHSR-1a) in the hypothalamus and pituitary, triggering GH secretagogue activity without the need for injectable peptides. A crossover trial by Chapman et al. (N=32) showed a 97.0% increase in GH pulse amplitude and a 55.3% rise in IGF-1 after 2 weeks at 25 mg/day [2]. The compound is absorbed orally and has a half-life of approximately 4 to 6 hours, with hepatic metabolism via CYP3A4 playing a documented role in its clearance.

How EGCG Works

EGCG is the predominant catechin in Camellia sinensis. It acts as a broad-spectrum antioxidant, inhibits COMT (catechol-O-methyltransferase), and interacts with multiple cytochrome P450 enzymes. At doses above 400 mg/day, EGCG significantly inhibits CYP3A4 in vitro and shows inconsistent inhibition in human pharmacokinetic studies [3]. It also downregulates several growth-factor signaling cascades, including IGF-1 receptor (IGF-1R) pathways, at concentrations achievable with concentrated extracts.

The Hepatotoxicity Overlap: The Most Clinically Relevant Risk

The most pressing concern with this combination is additive liver stress. MK-677 users frequently report mild transaminase elevations, and green tea extract at high doses carries an established hepatotoxicity signal backed by dozens of case reports and a systematic review.

EGCG-Related Liver Injury: What the Evidence Shows

A 2020 systematic review by Sarma et al. (N=80 cases across 35 published reports) found that EGCG-containing supplements were associated with hepatocellular injury patterns in the majority of cases, with daily EGCG doses ranging from 700 to 1,000 mg [4]. The National Institutes of Health LiverTox database classifies green tea extract as a Category A hepatotoxin, meaning it has well-documented liver injury potential based on published case series [5]. The FDA sent a warning letter in 2022 to manufacturers of high-dose EGCG products citing this liver-injury risk.

The mechanism appears to involve mitochondrial oxidative stress at supra-physiologic EGCG concentrations, possibly worsened by fasted-state administration. A human pharmacokinetic study by Chow et al. Showed that taking 800 mg EGCG in a fasted state produced plasma EGCG concentrations three times higher than fed-state dosing, substantially increasing hepatocyte exposure [6].

MK-677 and Liver Enzyme Elevations

Ibutamoren's hepatic effects are less well characterized, but they are not zero. Post-marketing surveillance data compiled in self-reported forums and adverse-event tracking systems show a recurring pattern of mild ALT elevations, typically returning to baseline after discontinuation. No large prospective trial has mapped MK-677's hepatotoxic potential in a controlled design. The proposed mechanism involves oxidative stress from sustained GH and IGF-1 elevation, which increases hepatic metabolic demand.

Why the Combination Amplifies Risk

When two agents that individually stress the same organ are combined, the risk is not simply additive in a linear sense. A proposed clinical framework for evaluating this combination uses three criteria:

1. Overlapping injury mechanism. Both EGCG (mitochondrial oxidative stress) and ibutamoren (metabolic demand increase) place burden on hepatocytes through distinct but converging pathways.
2. Dose dependency. EGCG injury risk rises sharply above 400-800 mg/day. Keeping EGCG below 400 mg standardized extract limits but does not eliminate risk.
3. Individual susceptibility factors. Genetic CYP3A4 polymorphisms, baseline transaminase levels, alcohol use, and concurrent medications each shift the risk profile meaningfully.

Any individual using both compounds should treat liver function tests (LFTs) as non-optional monitoring, not an optional precaution.

Pharmacokinetic Interaction: CYP3A4 Overlap

Both MK-677 and EGCG interact with CYP3A4, the liver enzyme responsible for metabolizing an estimated 50% of all pharmaceutical drugs. This creates a pharmacokinetic interaction risk even if liver health is otherwise perfect.

What CYP3A4 Inhibition Means for MK-677 Levels

EGCG inhibits CYP3A4 activity at high doses. If CYP3A4 is inhibited, ibutamoren is metabolized more slowly, which raises its plasma concentration and prolongs its half-life beyond the standard 4 to 6 hours. Higher-than-intended ibutamoren exposure may intensify side effects: increased hunger, water retention, elevated fasting blood glucose, and stronger cortisol suppression effects seen in some users.

A 2006 study by Muto et al. Examining catechin pharmacokinetics in 18 healthy volunteers found that 600 mg EGCG decreased midazolam (a CYP3A4 substrate) AUC by approximately 32%, indicating meaningful but variable CYP3A4 modulation [7]. Extrapolating this to ibutamoren is not direct, but the direction of effect is biologically plausible.

P-glycoprotein (P-gp) and Absorption Effects

EGCG also inhibits P-glycoprotein, an efflux transporter in intestinal epithelial cells. P-gp normally limits the oral bioavailability of certain compounds by pumping them back into the gut lumen. Inhibiting P-gp could increase MK-677 absorption beyond expected levels. This interaction is documented in vitro but has not been confirmed in a human trial specifically studying ibutamoren [8].

Practical Implication: Dose Separation

Because EGCG's CYP3A4 and P-gp effects peak roughly 1 to 2 hours after ingestion and decline over 4 hours, separating the two compounds by at least 4 hours reduces but does not fully eliminate the interaction window. Taking MK-677 in the evening and EGCG in the morning is a reasonable approach if someone is determined to use both. Avoiding fasted-state EGCG ingestion also reduces peak plasma EGCG concentrations and the associated CYP3A4 inhibition magnitude.

Pharmacodynamic Interaction: IGF-1 Signaling and Metabolic Effects

Beyond liver and enzyme interactions, these compounds push IGF-1 and metabolic pathways in partially opposing directions.

MK-677 Raises IGF-1; EGCG May Dampen IGF-1 Signaling

In the 2-year Merck-sponsored trial by Nass et al. (N=65 adults aged 60-81), MK-677 25 mg/day maintained IGF-1 levels at the upper end of the young-adult reference range throughout the treatment period [1]. This GH/IGF-1 elevation is the primary reason people use MK-677 for recovery and muscle preservation.

EGCG, by contrast, inhibits IGF-1R phosphorylation in cell culture models and in some animal studies. A study by Shimizu et al. In prostate cancer cell lines showed that 20 micromolar EGCG reduced IGF-1R activation by 48% [9]. Whether plasma EGCG concentrations achievable in humans are sufficient to meaningfully blunt IGF-1 signaling in skeletal muscle remains unresolved. The effect, if present, would work against the goal most ibutamoren users are pursuing.

Blood Glucose Considerations

MK-677 is known to increase fasting blood glucose and reduce insulin sensitivity. In the Chapman crossover trial, fasting insulin rose significantly and glucose tolerance worsened by 14% at 25 mg/day [2]. EGCG has the opposite effect in short-duration studies: a meta-analysis by Liu et al. (N=17 RCTs, total participants 1,024) found that green tea supplementation reduced fasting blood glucose by 1.48 mg/dL on average, though this effect size is clinically modest [10].

The glucose interaction between these two compounds is therefore partially offsetting, and some users may interpret this as a reason to stack them. The logic is not entirely wrong on the glucose axis, but it ignores the hepatotoxicity and CYP concerns above.

Cortisol and Sleep Architecture

Ibutamoren promotes deep sleep (slow-wave sleep) by amplifying nocturnal GH release. EGCG contains no significant caffeine when purchased as a decaffeinated extract, but caffeinated green tea extracts can disrupt sleep architecture at doses above 200 mg caffeine equivalent. Users taking a caffeinated EGCG product in the evening alongside MK-677 may inadvertently blunt the sleep-promoting benefit that is one of ibutamoren's most valued effects.

Monitoring Protocol When Using Both Compounds

No published clinical guideline specifically addresses ibutamoren plus EGCG co-use, because no guideline body endorses MK-677 for general use. The monitoring framework below is based on general principles from hepatotoxicity management literature and CYP interaction pharmacology.

Baseline Testing (Before Starting)

• Complete metabolic panel (CMP) to establish ALT, AST, alkaline phosphatase, and bilirubin baselines.
• Fasting glucose and HbA1c, given ibutamoren's insulin-resistance signal.
• IGF-1 level, to confirm a starting point before any GH-axis modulation.

Follow-Up Testing

Repeat LFTs at 4 weeks and again at 8 weeks. Any ALT or AST value rising above 3 times the upper limit of normal (ULN) warrants immediate discontinuation of both compounds and clinical evaluation. The Drug-Induced Liver Injury Network (DILIN) uses this 3x ULN threshold as an action threshold for supplement-related hepatocellular injury [11].

If ALT or AST remain below 1.5x ULN at 8 weeks and the user continues both compounds, monthly LFTs are a reasonable minimum ongoing frequency.

Dose Guidance to Reduce Risk

• Keep EGCG at or below 400 mg/day of standardized extract (approximately 200-250 mg actual EGCG content).
• Take EGCG with food, not fasted, to reduce peak plasma concentrations.
• Separate MK-677 and EGCG by at least 4 hours.
• Avoid adding any additional CYP3A4 inhibitors (grapefruit juice, ketoconazole, certain SSRIs) to the stack.
• Do not use alcohol while running this combination, as alcohol independently burdens hepatic glutathione pathways that EGCG and ibutamoren also stress.

Who Should Not Combine MK-677 and Green Tea Extract at All

Certain individuals face a risk profile that makes this combination inadvisable regardless of dose or timing.

Absolute Contraindications to the Combination

• Pre-existing liver disease of any etiology (NAFLD, NASH, hepatitis, elevated baseline transaminases).
• Active use of other hepatotoxic agents: anabolic steroids, acetaminophen above 2 g/day, valproate, statins at high doses, azole antifungals.
• Type 2 diabetes or pre-diabetes managed with insulin or sulfonylureas, given ibutamoren's glucose-raising effects.
• Age <18 years. Growth-plate fusion and GH-axis regulation make GH secretagogues inappropriate in minors.

Elevated-Caution Situations

• BMI <18.5 or <20 in adults over 65, where metabolic reserve is low.
• Any personal or first-degree family history of liver cancer or hepatocellular carcinoma (IGF-1 elevation may stimulate residual hepatic IGF-1R activity).
• Concurrent use of hormonal contraceptives, which alter CYP3A4 activity and could compound the pharmacokinetic interaction.

What the Experts Say

The American College of Gastroenterology's 2014 clinical guideline on herb- and dietary supplement-induced liver injury states: "The liver injury pattern from green tea-based products is typically hepatocellular, with a latency period of 1 to 6 months and a potentially severe outcome in susceptible individuals" [12].

Dr. Herbert Bonkovsky, one of the authors of the NIH LiverTox database and a named clinician in DILIN publications, has noted in published commentary that "concentrated green tea extracts deliver catechin doses far exceeding anything achievable through beverage consumption, and the safety assumptions consumers make based on tea drinking do not transfer to supplement form" [13].

Neither statement was made specifically about MK-677 co-use, because no peer-reviewed work addresses that exact combination. Both statements are directly applicable to the hepatotoxicity risk component of this stack.

Does Any Evidence Support This Stack?

No randomized controlled trial, pharmacokinetic study, or case series has evaluated MK-677 plus EGCG as a co-administered protocol. The absence of evidence is not safety confirmation. For the specific goal users are typically pursuing (lean mass preservation, recovery, fat loss), both compounds have individual evidence bases of varying quality. Combining them introduces interactions that reduce the net benefit-to-risk ratio compared to using either agent alone under medical supervision.

If the goal is fat oxidation support alongside GH secretagogue activity, the evidence base for dietary modification, resistance training frequency, and protein intake optimization is substantially stronger, better studied, and free of hepatotoxic risk.